4582 Stock Overview
Engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
SymBio Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥199.00 |
| 52 Week High | JP¥475.00 |
| 52 Week Low | JP¥146.00 |
| Beta | 0.75 |
| 1 Month Change | -17.08% |
| 3 Month Change | -22.57% |
| 1 Year Change | -19.43% |
| 3 Year Change | -82.62% |
| 5 Year Change | -67.22% |
| Change since IPO | -86.55% |
Recent News & Updates
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24
SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up
Aug 06Recent updates
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up
Aug 06Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge
Jun 11Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation
Feb 09If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%
Dec 18Shareholder Returns
| 4582 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -5.2% | 2.8% | 3.6% |
| 1Y | -19.4% | 12.8% | 16.3% |
Return vs Industry: 4582 underperformed the JP Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: 4582 underperformed the JP Market which returned 16.3% over the past year.
Price Volatility
| 4582 volatility | |
|---|---|
| 4582 Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.2% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4582 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4582's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 109 | Fuminori Yoshida | www.symbiopharma.com |
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. It offers SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administrator under the TREAKISYM name. The company also engages in the development of SyB L-1101, an intravenous formulation, which completed Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase I/II clinical trial in combination with AZA to treat HR-MDS.
SymBio Pharmaceuticals Limited Fundamentals Summary
| 4582 fundamental statistics | |
|---|---|
| Market cap | JP¥9.12b |
| Earnings (TTM) | -JP¥4.02b |
| Revenue (TTM) | JP¥3.07b |
3.0x
P/S Ratio-2.3x
P/E RatioIs 4582 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4582 income statement (TTM) | |
|---|---|
| Revenue | JP¥3.07b |
| Cost of Revenue | JP¥687.87m |
| Gross Profit | JP¥2.38b |
| Other Expenses | JP¥6.40b |
| Earnings | -JP¥4.02b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -87.69 |
| Gross Margin | 77.57% |
| Net Profit Margin | -131.05% |
| Debt/Equity Ratio | 0% |
How did 4582 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 02:00 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SymBio Pharmaceuticals Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathaniel Calloway | Edison Investment Research |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |